Navigation Links
Watson Launches Generic Exelon®
Date:7/1/2010

MORRISTOWN, N.J., July 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules.  Exelon® is used to treat dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) in people with Alzheimer's disease.

Under the terms of the settlement agreement announced on December 6, 2007, Novartis granted Watson a license to its U.S. patents covering Exelon® for a generic version of Exelon®. Further details concerning the settlement have not been disclosed. Watson's Abbreviated New Drug Application for its generic version of Exelon® was approved by the U.S. Food and Drug Administration on January 8, 2008.

For the twelve months ending April 30, 2010, Exelon® had total U.S. sales of approximately $425 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended March 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Exelon® is a registered trademark of Novartis AG Corporation.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
2. Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference
3. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
4. Watsons Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval
5. Watson Launches Generic Version of LIPITOR® in Canada
6. Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference
7. Watson Reaches Settlement with Teva Over Seasonale(R)
8. Watson Confirms EVISTA(R) Patent Challenge
9. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th
10. Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference
11. Watson Confirms Trilipix(R) Patent Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 ... biopharmaceutical company focused on late-stage drug development, today ... Pharma of pivotal batches required for registration ... Administration (FDA). This follows Kitov,s announcement ... trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology:
(Date:5/30/2016)... Salt Lake City, Utah (PRWEB) , ... May ... ... health insurance reimbursement for small businesses, announced today the publication of an original ... helps business owners and health insurance professionals understand how Zane Benefits complies with ...
(Date:5/29/2016)... Aliso Viejo, CA (PRWEB) , ... May 29, 2016 , ... ... Web Volume 3 let's the user control the style of their project," said Christina ... a set of 30 self-animating web-themed intros created exclusively for use in Final Cut ...
(Date:5/28/2016)... ... , ... In a part of the city where’s it’s easy to spot the neon lights ... is hoping to attract diners with a taste for real food. , On May ... to Cornerstone Grill, an urban casual restaurant focusing on dishes made by hand with wholesome, ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... annual campaign returns for a third time to shed lights on the variety of ... resources and inspirational stories, “Nurse Appreciation” tackles why this career has gone from being ...
(Date:5/27/2016)... ... ... Beleza Medspa has initiated a new program to assist active ... time that Coolsculpting is being used for for more than just cosmetic purposes. ... the prescribed body-fat standard, measured by the circumference-based tape method. The tape-test is ...
Breaking Medicine News(10 mins):